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The development of angiotensin-converting enzyme inhibitors (ACE inhibitors) has been
one of the most remarkable stories in the treatment of cardiovascular diseases. Angiotensin
converting enzyme inhibitors have several acute and sustained hemodynamic effects that are
beneficial in the presence of left ventricular (LV) dysfunction. They increase cardiac output
and stroke volume and reduce systemic vascular resistance as well as pulmonary capillary
wedge pressure. The hemodynamic benefits are associated with improvement in the signs and
symptoms of congestive heart failure (CHF) as well as decreased mortality, regardless of the
severity of CHF. In patients with asymptomatic LV dysfunction, therapy with ACE
inhibitors prevented the development of CHF and reduced hospitalization and cardiovascular
death. They also increase survival when administered early after an acute myocardial
infarction (MI). Most recently, ACE inhibition was associated with improved clinical
outcomes in a broad spectrum of high-risk patients with preserved LV function. The
mechanism of ACE inhibitors benefits is multifactorial and includes prevention of progressive
LV remodeling, prevention of sudden death and arrhythmogenicity and structural stability of
the atherosclerotic process. Evidence suggests that ACE inhibitors are underutilized in
patients with cardiovascular diseases. Efforts should be directed to prescribe ACE inhibitors
to appropriate patients in target doses. It is reasonable to believe that ACE inhibitors have a
class effect in the management of LV dysfunction with or without CHF and acute MI.
Whether the same is true for ACE inhibitors in the prevention of ischemic events is not
known yet. (J Am Coll Cardiol 2001;37:1757–64) © 2001 by the American College of
Cardiology
The development of angiotensin-converting enzyme (ACE)
inhibitors has been one of the most remarkable stories in the
treatment of cardiovascular diseases. In the 1960s and
1970s, neurohormonal activation was considered a necessary
mechanism to insure survival for patients with left ventric-
ular (LV) dysfunction. However, this was proven to be
incorrect, and blockade of the renin-angiotensin system and
other neurohormonal systems proved to be of great benefit
for patients with LV dysfunction. The first step in the
development of ACE inhibitors was to document their
hemodynamic properties. Hemodynamic improvement cor-
related with symptomatic improvement, and by the early
1980s the role of ACE inhibitors expanded from use in
hypertension to symptomatic therapy for patients with
congestive heart failure (CHF). In the 1980s and early
1990s, it was demonstrated that ACE inhibitors provided a
survival benefit for patients with LV dysfunction by atten-
uating the progressive process of LV remodeling. Moreover,
ACE inhibitors have been shown to improve outcome for
patients when administered in the early postinfarction
period. Most recently, ACE inhibition has been associated
with improvement in the clinical outcomes in a broad
spectrum of high-risk patients with preserved LV function.
This review discusses the magnitude of ACE inhibitors
benefit in various cardiac patients. It also describes the
mechanism of action and appropriate dosing of these agents.
BENEFITS OF ACE
INHIBITORS SEEN IN PATIENTS WITH CHF
Effects on hemodynamics. Angiotensin-converting en-
zyme inhibitors have several acute and sustained hemody-
namic effects that are particularly beneficial in the presence
of LV dysfunction. The hemodynamic effects of oral cap-
topril in patients with CHF were examined by several
investigators (1–4). A single dose of captopril increased
cardiac output and stroke volume and reduced systemic and
pulmonary vascular resistance as well as pulmonary capillary
wedge pressure (1,4). Hemodynamic benefits were observed
at 30 min, peaked at 90 min and persisted for at least 6 h (1).
These favorable hemodynamic changes were sustained after
eight weeks of continuous therapy. Enalapril produced
comparable effects (5,6), and the benefits were maintained
with long-term therapy. The hemodynamic and hormonal
effects of ramipril compared with captopril were studied in
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patients with moderate to severe heart failure (7). Compared
with 12.5 mg of captopril, 5 mg of ramipril was associated
with slower onset of action; however, the benefits were
maintained for a longer duration (7). With 10 mg of
ramipril, both hemodynamic and hormonal benefits were
observed quicker and maintained for an even longer dura-
tion (7). Similar hemodynamic benefits were demonstrated
using the ACE inhibitors fosinopril and lisinopril (8–10).
When compared with other vasodilators, ACE inhibitors
produce a balanced systemic arteriovenous vasodilation.
They also decrease salt and water retention by reducing
aldosterone synthesis (11). Clinically, these beneficial he-
modynamic effects translate into considerable improvement
in LV function and symptoms in patients with CHF. Thus,
ACE inhibitors improve hemodynamic parameters acutely
in patients with CHF, and such improvement persists over
time.
Effects on signs and symptoms of CHF. The Captopril
Multicenter Group conducted a study designed to test the
clinical efficacy and safety of using ACE inhibitor therapy in
patients with CHF (12). In this study, patients with heart
failure treated with digoxin and diuretic therapy were
randomized to receive captopril or placebo for a 12-week
period. The study demonstrated that captopril was associ-
ated with a lessening of the signs and symptoms of CHF.
The symptoms compared were dyspnea, fatigue, orthopnea
and edema. Using exercise treadmill testing, captopril re-
sulted in improved exercise capacity when compared with
the placebo patients. Captopril was compared with digoxin
in the Captopril-Digoxin Multicenter trial (13). The cap-
topril treated group showed significant improvement in
exercise time, New York Heart Association (NYHA) func-
tional class and the need for increased diuretics or hospital-
ization for worsening CHF. Similar results were noted with
the once daily ACE inhibitor fosinopril (14). In this study,
patients had symptoms that were milder when compared
with the symptoms seem in the previous study. Patients
received fosinopril or placebo for six months with concom-
itant diuretic therapy, but not digitalis. Patients receiving
fosinopril had improved exercise treadmill time. They were
more likely than the placebo group to show improvement in
the amount of dyspnea, fatigue and paroxysmal nocturnal
dyspnea as well as a reduction in hospitalizations due to
worsening heart failure. These benefits were confirmed in
the in fosinopril Efficacy/Safety trial (15).
In patients with severe CHF, therapy with ACE inhib-
itors will improve peak exercise performance and reduce the
symptoms of CHF. In the Cooperative North Scandinavian
Enalapril Survival study (CONSENSUS) I trial, patients
who had symptoms at rest were randomized to receive the
ACE inhibitors enalapril or placebo (16). Patients treated
with enalapril were more likely to improve their NYHA
classification than placebo-treated patients (42% vs. 22%).
Similar results were reported using other ACE inhibitors in
patients with NYHA class II to IV CHF (17–19).
Effects on survival. Documentation of the survival benefits
of ACE inhibitors is one of the most important advances in
the management of LV dysfunction. Angiotensin-
converting enzyme inhibitors are now well-established
drugs used in the treatment of CHF.
The CONSENSUS I study was the first major mortality
trial of ACE inhibitors therapy (16). The study demon-
strated a 40% reduction in mortality in patients with severe
NYHA class IV symptoms. The mortality at one year was
reduced from 52% with placebo to 36% with enalapril.
Survival benefits were maintained at a two-year follow-up
among those allocated to the ACE inhibitor therapy (20).
The Studies Of LV Dysfunction (SOLVD) treatment trial
demonstrated that ACE inhibitors could benefit patients
with CHF and less severe symptoms—NYHA class II and
III symptoms (21). In this study, a total of 2,569 patients
with LV ejection fraction #35% (mean 25%) were random-
ized to receive either enalapril or placebo and followed for
an average of 41 months. Treatment with enalapril reduced
the overall risk of death by 16%; mortality was 40% in the
placebo-treated group compared with 35% in the enalapril-
treated group. Cardiovascular death was reduced by 18%,
and the combined end point of death or hospitalization for
CHF was reduced by 26%. This translated into the preven-
tion of 50 deaths and 350 hospitalizations for every 1,000
patients with CHF treated with enalapril for three years.
The V-HeFT II trial compared a regimen hydralazine/
isosorbide dinitrate to enalapril in patients with CHF class
II and III NYHA symptoms (22). The study demonstrated
a survival advantage with ACE inhibitor therapy; treatment
with enalapril was associated with a 28% reduction in the
risk of death at two years compared with the vasodilator
combination.
In the Acute Infarction Ramipril Efficacy trial, long-term
ACE inhibitor therapy was tested in a group of survivors of
acute myocardial infarction (MI) with transient signs and
symptoms of CHF (23). A total of 2,006 patients were
enrolled and randomized to either the ACE inhibitor
ramipril group or placebo group within 3 to 10 days after
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MI. The active therapy group experienced a 27% reduction
in the risk of death after a mean follow-up of 15 months.
This benefit was maintained for five years after randomiza-
tion (24).
Thus, ACE inhibitors had demonstrated efficacy in
prolonging life in patients with all degrees of CHF associ-
ated with LV systolic dysfunction. They also demonstrated
efficacy in preventing death in a population of patients with
acute MI and CHF.
BENEFITS SEEN IN ASYMPTOMATIC
PATIENTS WITH LV DYSFUNCTION
The benefits of ACE inhibitor therapy on survival in
patients with symptomatic CHF prompted investigators to
study the effects of ACE inhibitors in patients with asymp-
tomatic LV dysfunction. The Survival And Ventricular
Enlargement (SAVE) trial randomized 2,231 patients 3 to
16 days after MI with LV ejection fraction #40% without
symptomatic heart failure to captopril or placebo (25). After
an average 3.5 years of follow-up, the captopril group had a
19% reduction in all-cause mortality, a 21% reduction in
cardiovascular death, a 22% reduction in the incidence of
heart failure requiring hospitalization and a 25% reduction
in the incidence of recurrent MI.
The SOLVD prevention trial was designed to determine
whether enalapril would reduce mortality and morbidity in
a broad spectrum of asymptomatic patients with LV dys-
function (26). In this study, 4,228 patients with an LV
ejection fraction #35% were randomized to receive either
enalapril or placebo. None of these patients were on therapy
for heart failure. The mean follow-up period was 37 months
(15 to 62 months). There was a trend toward a lower rate of
overall death noted in the enalapril group with a risk
reduction of 8%; cardiovascular death was also reduced by
12%, but it did not reach statistical significance. However,
the combined end point of death or the development of
CHF was reduced significantly (risk reduction 5 29%). In
the Trandolapril Cardiac Evaluation (TRACE) trial, pa-
tients with documented LV dysfunction after MI were
randomized to either trandolapril or placebo within three to
seven days of infarction (27). Mortality was significantly
reduced from 42.3% in the placebo group to 34.7% in the
trandolapril-treated group.
BENEFITS SEEN IN PATIENTS WITH ACUTE MI
For many years it was believed that therapeutically induced
hypotension would decrease coronary blood flow and be
harmful for patients suffering an acute MI. The CONSEN-
SUS II trial was published in 1992 and reinforced this
hypothesis (28). In this trial, enalapril was started within
24 h of acute MI. The initial dose was given intravenously
and was associated with a higher risk of early hypotension.
Although there was no worsening of heart failure in the
patients randomized to ACE inhibitor therapy, there was
no significant effect on survival at either one or six months.
The lack of survival benefits and an excess of deaths in the
enalapril group who had early hypotension resulted in
premature termination of the study.
After demonstration of the remarkable benefits of ACE
inhibitors in patients with acute MI by the SAVE investi-
gators, interest resurfaced to examine their effects in the
early post-MI period. A careful oral titration of ACE
inhibitors in the immediate postinfarct period was used to
avoid the development of hypotension. Subsequently, the
benefits of early postinfarction ACE inhibitor therapy were
demonstrated in large clinical trials. In the third Gruppo
Italiano per lo Studio della Sopravvivenza nell’Infarto Mio-
cardico (GISSI) trial, patients with acute infarctions were
randomized to receive the ACE inhibitor lisinopril, 5 mg
initial dose and then 10 mg daily versus placebo (29).
Therapy was started within 24 h of acute infarction. At six
weeks, mortality and the combined end point of mortality
and LV dysfunction were reduced in the ACE inhibitor-
treated patients. Benefits were seen despite concomitant
therapy with aspirin, thrombolytics and beta-adrenergic
blocking agents. In the SAVE trial, clinical benefit was not
apparent until after 11 months of therapy and was due to
remodeling of noninfarcted myocardium (25). The early
benefit of ACE inhibitor therapy in the third GISSI trial
suggests that starting ACE inhibitors within 24 h has an
effect on the infarcted myocardium either by limiting infarct
size or by reducing infarct expansion. The International
Study of Infarct Survival (ISIS)-4 trial showed similar
results (30). In that trial, oral captopril was administered
within 24 h of acute MI. At five weeks, survival of patients
receiving captopril was better than that of the placebo
group. The benefit was greatest in high-risk patients with
prior MI, anterior ST elevation and LV dysfunction. Per-
haps the most convincing clinical evidence that early ACE
inhibitors therapy affects the infarcted myocardium is from
the Survival of Myocardial Infarction Long-term Evalua-
tion (SMILE) trial (31). Patients were randomized to the
ACE inhibitors zofenopril or placebo, which was adminis-
tered for only six weeks after acute MI. At the end of six
weeks, the combined end point of death and incidence of
CHF were reduced in the zofenopril patients. After one
year, mortality was lower in the ACE inhibitor-treated
group than it was in the placebo group. The short duration
of treatment started early after infarction would not be
expected to affect remodeling of noninfarcted myocardium
as in the SAVE trial. All patients in the SMILE trial had
anterior MI, which is the most likely group to benefit from
the effects of early ACE inhibitor therapy on reduction of
infarct size and attenuation of myocardial infarct expansion.
Similar benefits of ACE inhibitor therapy after MI were
demonstrated using captopril in the Chinese Cardiac study.
However, because of the small size of the trial, mortality
advantage was not statistically significant (32,33). The
Placebo-Controlled Randomized ACE Inhibitor Com-
parative Trial In Cardiac Infarction and LV Function
(PRACTICAL) study compared enalapril versus captopril
on LV function and survival after acute MI (34) and
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demonstrated comparable benefits of both ACE inhibitors
on LV function and attenuation of LV dilation.
The benefits of ACE inhibitors in patients with acute MI
complicated by CHF were addressed by the Acute Infarc-
tion Ramipril Efficacy trial investigators, as discussed earlier
in this review. The timing of initial ACE inhibitor therapy
was studied in the Healing and Early Afterload Reducing
Therapy (HEART) trial (35). The study compared the
benefits of ramipril when administered either early (within
24 h) or late (after two weeks) after the onset of acute MI.
Although the trial was terminated prematurely due to the
obvious benefits of early administration of ACE inhibitors
after MI demonstrated by ISIS-4 and the third GISSI trial,
the study demonstrated that ramipril, when started early
after MI, attenuated LV remodeling and increased ejection
fraction when compared with delayed initiation of ACE
inhibitors.
Thus, early administration of ACE inhibitors after acute
MI for a few weeks is associated with five lives saved per
1,000 treated (36). Administration of ACE inhibitors at a
later time is associated with fewer benefits. The maximum
benefits are seen in patients with LV dysfunction with or
without overt heart failure. The development of hypoten-
sion is associated with increase risk of death and should be
avoided (36,28).
BENEFITS SEEN IN HIGH-RISK
PATIENTS WITHOUT LV DYSFUNCTION
Results from the SAVE and SOLVD trials demonstrated
that ACE inhibitor therapy after MI was associated with a
reduction of recurrent MI (25,26,37,38). The benefit was
independent of the degree of LV dysfunction and was not
evident until 6 to 12 months after the initiation of therapy
(25,38). This suggested additional ACE inhibitor benefits
not related to hemodynamic effects. Observed benefits could
be due to structural effects such as delay of progression of
coronary artery disease (CAD) or stabilization of athero-
sclerotic plaques (39).
The Heart Outcomes Prevention Evaluation (HOPE)
study (40) explored whether ACE inhibition with ramipril,
10 mg/day, could prevent cardiovascular events or stroke in
high-risk patients without known LV dysfunction or CHF.
The study was terminated prematurely because of a clear
benefit of ACE inhibitor therapy. Treatment with ramipril
was associated with a 22% reduction in the risk of a
cumulative primary end point of cardiovascular death, MI or
stroke. The relative risk of death from any cause with
ramipril was 0.84 (p 5 0.005) compared with placebo.
Therapy with ramipril was also associated with a significant
reduction in the rate of revascularization, cardiac arrest and
the development of CHF.
While previous trials have proven that ACE inhibitors
are effective in patients with LV dysfunction, the HOPE
study proved that ACE inhibition is protective in a broad
range of patients without baseline LV dysfunction or CHF.
Whether prevention of ischemic events by ACE inhibitors
in patients without LV dysfunction is a class effect or
whether or not lower-risk patients can benefit from their use
is currently under investigation.
MECHANISMS OF ACE
INHIBITORS BENEFICIAL EFFECTS
The mechanisms of ACE inhibitors benefits are multifac-
torial. In any particular patient, one or more of the following
mechanisms may play an important role in producing
clinical benefits.
Prevention of CHF. Loss of myocardium as the result of
acute MI or muscle damage seen in nonischemic cardiomy-
opathy results in a decline in cardiac performance. A series
of compensatory mechanisms are activated to maintain
cardiac output, including enhanced sympathetic tone and
activation of the renin-angiotensin endocrine axis (41,42).
Enhanced sympathetic tone leads to increased contractility
of the remaining functional myocardium and to an increase
in systolic and diastolic wall stress. Increased wall stress
stimulates myocyte hypertrophy, which returns wall stress
levels towards normal. If the amount of damaged myocar-
dium is limited, compensatory mechanisms can be sufficient
to minimize chamber enlargement and LV hypertrophy.
When the amount of damaged myocardium is extensive,
the increase in LV filling pressures and resulting chamber
distension can exceed the hearts ability to increase LV mass.
When hypertrophy is inadequate to compensate for lost
myocardium, the increased wall stress continues to stimulate
further LV dilation that goes beyond that necessary to
maintain cardiac performance. A vicious cycle is initiated in
which LV dilation progressively increases wall stress, which
stimulates even further increases in LV cavity size. The
balance between cavity dilation and maintenance of cardiac
function is upset, and progressive LV dilation exceeds that
which is compensatory and becomes a pathologic process.
In experimentally induced MI, a progressive increase in
LV volume has been demonstrated (42). After coronary
ligation resulting in a moderate to large MI, the extent of
LV enlargement has been shown to be related not only to
infarct size, but also to the duration of time after the
infarction. Measurements of pressure-volume relationships
showed that, for similar end-diastolic pressures, LV volume
progressively increased over time. The progressive volume
increase is not due to LV distension. It is due to structural
changes in both infarcted and noninfarcted myocardium.
Progressive increases in LV volume can be detected by
noninvasive imaging with two-dimensional echocardiogra-
phy, radionuclide ventriculography and magnetic resonance
imaging. Progressive enlargement of the LV is viewed as a
continuous process with progressive cardiac chamber en-
largement occurring as a precursor to, and subsequently
continued during, the clinical manifestation of CHF. Al-
teration or prevention of progressive ventricular enlarge-
ment has an effect on morbidity and mortality.
Several large clinical trials demonstrated that treatment
with ACE inhibitors in patients with LV dysfunction would
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slow the progression of pump failure (16,21,25–27). Antag-
onism of neurohormonal activation by ACE inhibitors may
slow the rate of deterioration of LV function.
On the cellular level, beside stimulation of myocytes
hypertrophy as discussed earlier in the text, elevated renin-
angiotensin-aldosterone levels promote fibrosis and collagen
deposition that lead to a stiff ventricle and progressive LV
dysfunction (43,44). Therapy with ACE inhibitors im-
proved myocyte contractile function (45), prevented non-
myocyte cellular proliferation and collagen deposition (45,46)
and prevented myocyte hypertrophic response (45,46).
Prevention of ischemic events. There are several mecha-
nisms whereby ACE inhibitors can prevent ischemic events
and recurrent acute MI. Activation of the renin-angiotensin
system has been shown to be an independent predictor of
ischemic events. In a group of mild to moderate hyperten-
sive patients, an elevated renin profile was an independent
predictor of future acute MI (47). Moreover, angiotensin II
has a proischemic vascular effect by causing vasoconstriction
and promoting the growth and migration of vascular
smooth muscle cells (48). This causes an increase in smooth
muscle cell enzyme, an increase in free radical production
and promotes the oxidation of low-density lipoprotein
cholesterol contributing to atherosclerotic progression.
Angiotensin-converting enzyme inhibitors are shown to
counteract the vasoconstriction of the atherosclerotic coro-
nary arteries. Therapy with ACE inhibitors has been dem-
onstrated to prevent endothelial dysfunction in animal
(49–53) as well as human experiments (54–58). The ben-
efits appear to be related to the ability of ACE inhibitors to
release local vasodilators such as nitric oxide and bradykinins
as well as antagonizing the effects of angiotensin II (59).
Additionally, ACE inhibition has been shown to counteract
several atherosclerotic processes including thrombosis, low-
density lipoprotein oxidation, proliferation of vascular
smooth muscle cells and local accumulation of neutrophils
(60). Activation of the renin-angiotensin system has pro-
thrombotic effects; ACE inhibitors increase plasma levels of
plasminogen activator inhibitor-1 and inhibits endogenous
fibrinolysis (61,62). Preliminary data have shown that ACE
inhibition improves endogenous fibrinolytic function (63).
Prevention of sudden death. In addition to reduction of
cardiac death by prevention of the development and pro-
gression of CHF, the reduction of sudden death demon-
strated in clinical trials suggests an additional mechanism of
benefit (22,27,64–66). The mechanism by which ACE
inhibitors prevents sudden death is not well understood.
Sudden death is likely to be due to sudden ischemia or
arrhythmic events (67). Neurohormonal modulation by
ACE inhibitors may reduce sudden vasoconstriction and,
thus, arrhythmogenesis. In isolated perfused rat hearts,
ACE inhibitors increased glycogen, adenosine triphosphate
and coronary flow and decreased the incidence of ventricular
fibrillation (68). These benefits have been attributed to both
blockade of angiotensin II production and inhibition of
bradykinin breakdown, which may stimulate the production
of various vasodilators like prostaglandins and nitric oxide
(69).
Additionally, ACE inhibitors may suppress the release of
catecholamines (70), decrease calcium overload (71,72) and
suppress endogenous endothelin secretion, which may ac-
count for less ventricular dysfunction and arrhythmias (73).
Recently, it was found that patients carrying the ACE DD
genotype with angiotensin II type 1C allele are at a higher
risk for malignant ventricular arrhythmias (74).
After acute MI. Animal experiments suggest several
mechanisms that could explain the early post-MI ACE
inhibitor benefits. In canine experimental infarctions, cap-
topril started after coronary artery occlusion increased en-
docardial blood flow, which resulted in reduced infarct size
(75). Similar results were demonstrated in patients who
received ACE inhibitor therapy after infarction, and infarct
size was reduced (76).
Angiotensin-converting enzyme inhibitor therapy may
benefit patients in the early post-infarction period by yet
another mechanism. Infarct expansion (a thinning and
dilation of infarcted tissue), which leads to increased mor-
tality, LV chamber enlargement and aneurysm formation, is
attenuated when captopril is started less than 24 h after
acute MI (77). In experimental rat MI, treatment with
ACE inhibitors reduced the extent of infarct expansion
when measured two weeks after infarction (78).
Angiotensin-converting enzyme inhibition was started 2 h
after infarction, which is too late in rats to have any effect on
infarct size. Reduction of infarct expansion has the potential
to reduce the risk of cardiac rupture, which is a rare and
usually fatal condition (79). However, it will benefit more
patients by reducing the extent of LV dilation (42,80–83).
While some degree of LV dilation will result from loss of
myocardium due to the acute infarction to compensate for
the loss of functioning myocardium, infarct expansion will
result in further cardiac dilation that goes beyond what is
compensatory. An expanded infarct can result in an LV
cavity size 20% to 40% over compensatory dilation (84).
Left ventricular infarct expansion is associated with in-
creased mortality and acts as a stimulus for remodeling of
noninfarcted myocardium resulting in more cardiac dilation.
UTILIZATION AND DOSING OF ACE INHIBITORS
Despite the overwhelming evidence of the effectiveness of
ACE inhibitors in the management of patients with LV
dysfunction, there is evidence that they are used in too few
patients and often at suboptimal doses (85–87). Underuti-
lization may result from concerns for adverse effects. Several
large clinical trials showed that ACE inhibitors are safe and
exceptionally well-tolerated by most patients, and the side
effects are generally reversible after discontinuation of the
medication. Thus, a trial of ACE inhibitors is warranted in
all candidates unless specific contraindications exist.
Angiotensin-converting enzyme inhibitors should be started
at low doses and titrated to their proven effective dose. The
Assessment of Treatment with Lisinopril And Survival
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(ATLAS) study indicated that a high dose of the ACE
inhibitors lisinopril was superior to a low dose in reducing
the risk of major clinical events in patients with CHF (88).
A similar dosing effect was seen in patients after MI treated
with ramipril (35). In patients with acute MI, ACE inhib-
itors should be administered early after infarction (within
24 h from onset of symptoms) and then continued indefi-
nitely in the presence of LV dysfunction. With the recent
publication of the HOPE trial, all post-MI patients or
patients who are at high risk for CAD should be treated
with ACE inhibitors indefinitely, even with normal LV
function.
Table 1 summarizes the initial and the target doses of
various ACE inhibitors. The initial dose should be lower if
the patient’s serum sodium concentration is ,135 mmol/L,
which indicates a high level of plasma renin activity, or if
serum creatinine is $250 mmol/L (approximately 3.0 mg/
dl). Mild, asymptomatic hypotension and mild azotemia are
acceptable side effects of therapy with ACE inhibitors and
are an indication to reduce the diuretic dose if the patient is
not volume overloaded. Particular attention should be prac-
ticed to avoid the development of hypotension in patients
with an acute MI, as hypotension may adversely affect the
remodeling process in the immediate post-infarction period
and can lead to increased mortality. Progressive deteriora-
tion of renal function or the development of a significant
hyperkalemia or hypotension should prompt an immediate
discontinuation of the therapy. Angioedema is a rare, but
life-threatening, complication of ACE inhibitor therapy
and should be an absolute contraindication to future use of
all ACE inhibitors. Angiotensin-converting enzyme inhib-
itors should be avoided in pregnant women since they are
associated with adverse fetal effects (89).
Angiotensin-converting enzyme inhibitors tend to con-
serve potassium by reducing the secretion of aldosterone.
Consequently, hypokalemia induced by diuretics can often
be prevented without the need for supplemental potassium
or a potassium-sparing diuretic. Accordingly, ACE inhibi-
tors should not be instituted at a time when the serum
potassium is .5.5 mmol/L. Caution should be practiced
about stopping ACE inhibitors because of cough. Alterna-
tive causes of cough, including worsening heart failure,
should be considered before discontinuing an ACE inhib-
itor. If the cough is intolerable for the patient and no other
cause is identified, then switching to another ACE inhibi-
tor, such as fosinopril, may be beneficial rather than avoid-
ing all ACE inhibitors (90).
FUTURE USE OF ACE INHIBITORS
Several large clinical trials demonstrated similar benefits of
various ACE inhibitors in patients with LV dysfunction or
CHF. Thus, it is reasonable to believe that ACE inhibitors
have a class effect in the management of LV dysfunction
with or without CHF. Similarly, ACE inhibitors benefits
after MI should be considered a class effect. Whether the
same is true for ACE inhibitors in the prevention of
ischemic events is not clear. Data from the SAVE and
SOLVD trials demonstrated that both captopril and enala-
pril are effective in preventing ischemic events in patients
with LV systolic dysfunction. On the other hand, ramipril is
the only ACE inhibitor so far shown to prevent ischemic
events in patients without LV dysfunction. Moreover, the
benefit of ACE inhibitors in patients at a lower risk than the
HOPE population has not been established.
Currently, two ongoing clinical investigations are intend-
ing to answer some of these questions. First the Prevention
of Events with ACE Inhibition (PEACE) trial (91) is
investigating whether trandolapril can prevent MI and
cardiovascular events in patients with CAD and normal
baseline ejection fraction. Second, the European Trial of
Reduction of Cardiac Events with Perindopril in Stable
CAD (EUROPA) (92) is assessing whether perindopril can
prevent MI, unstable angina and cardiovascular events in
patients with stable CAD and no CHF; patients with LV
dysfunction are not excluded.
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